Lilly dominates GLP-1 medicines (Mounjaro, Zepbound) and diabetes therapies; news centers on pricing, labeling, and growth ahead of rivals.
UK pharmacies are now able to offer orforglipron (Foundayo), the second GLP-1 pill for weight loss, following MHRA approval. The pill, manufactured by Eli Lilly, is available initially by private prescription while NICE assesses a potential NHS rollout in England. It targets BMI thresholds (30+, or 27-30 with weight-related conditions) and is taken daily with no food or water restrictions.
New observational data suggests Shingrix vaccination in older adults is associated with lower cardiovascular risk and reduced dementia incidence over multi-year follow-ups. Studies compare Shingrix to Zostavax and find reductions in heart disease, stroke, and dementia, with stronger signals in men for heart outcomes.
Investors have pushed new biotech winners — from Novo Nordisk’s semaglutide pill to startups tackling baldness and targeted autoimmune drugs — while market enthusiasm has cooled for some forecasts. Novo Nordisk has released a daily weight‑loss pill used by over 1.5 million people; hair‑loss startups have sent small caps soaring; India’s low‑cost GLP‑1 generics have underperformed expectations.
Eli Lilly has agreed to acquire privately held Merida Biosciences for up to $2.88 billion in cash. Merida develops treatments targeting auto-antibodies for autoimmune diseases, with MER511 in early-stage trials for Graves’ disease and thyroid eye disease. The deal expands Lilly’s immunology pipeline amid strong demand for obesity drugs.
The White House has announced that most favored nation pricing will align U.S. drug prices with the lowest prices abroad, with several manufacturers set to participate. Officials say the move will lower costs for Americans and expand constraints on pricing practices.
Nvidia has reported stronger-than-expected results, guiding to 70% revenue growth for fiscal 2028 amid robust AI demand. Amazon plans to buy 2 million Nvidia GPUs, underscoring sustained AI infrastructure buildout. Analysts note the market is reassessing hype around AI as Nvidia shows durable demand and a diversified customer base.
A synthesis of recent sleep studies shows wearables may misjudge sleep quality, narcolepsy treatment advances gain regulatory traction, and weekend catch-up sleep ties to lower hypertension risk, prompting a nuanced view of how to monitor and improve sleep.
The Department of Justice has reached a settlement with Abbott over concerns about a Michigan plant that produced a major share of the U.S. infant formula supply. Regulators cite unsanitary conditions; Abbott reports no admission of fault and notes negative tests on unopened product from infants’ homes. The deal directs corrective steps and allocates funds to regulators and whistle-blowers.
Companies are reviewing coverage for GLP-1 weight-loss drugs as costs rise. Some have already trimmed benefits, while others cite long-term employee health benefits as a reason to maintain or adjust coverage. The trend could raise healthcare costs for employers and influence benefits strategies.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.
Walmart has expanded benefits for associates, adding 12 weeks of neonatal ICU leave and enabling second opinions for rare conditions. It also joins Novo and Lilly drug coverage for Type 2 diabetics at no cost, while premium increases are minimized. The moves come ahead of open enrollment and build on years of compensation improvements.
The Federal Trade Commission and seven states have asked a federal judge to hold ex-pharma executive Martin Shkreli in contempt for allegedly violating a 2022 lifetime ban by trading pharmaceutical stocks and discussing the industry in livestreams since his release from prison.
Anthropic is pitching its Claude models as a catalyst for rapid biological discovery, framing AI as a force to accelerate drug research. Its S-1 highlights life-sciences ambitions and partnerships with pharma giants while Isomorphic Labs is pursuing AI-designed medicines, aiming to design drugs without traditional lab work.
New long-term studies show Wegovy and tirzepatide reduce BMI in children and adolescents, raising hopes for obesity treatment. The FDA now requires warnings about rare eye risk NAION across GLP-1 therapies. Experts caution about long-term effects and equity in access as results signal a potential shift in pediatric care.
The FDA has required makers of GLP‑1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, to add a warning about a rare eye condition called non‑arteritic anterior ischemic optic neuropathy (NAION). The agency has found a small increased risk in trial and real‑world data and is urging patients with sudden, painless vision loss in one eye to seek prompt ophthalmology evaluation.
The White House has withdrawn Heidi Overton’s nomination to lead the FDA after insufficient Senate support. Republican concerns over vaccine policy and abortion-related issues have stalled confirmation, with the HELP Committee vote now in doubt as the administration considers a replacement.